0
0
The Central Drugs Standard Control Organisation (CDSCO) of India has initiated a significant move aimed at improving medicine accessibility for blind and visually impaired individuals by proposing the introduction of Braille labeling and QR code-based voice assistance on medicine packages. This proposal responds to ongoing challenges faced by this vulnerable population in identifying medicines, their names, and expiry details independently. The CDSCO has invited public and stakeholder comments on the recommendations based on detailed examinations by the Drugs Consultative Committee (DCC) and a dedicated subcommittee, signaling a progressive step towards inclusive healthcare measures in India.
Key Developments and Recommendations
The initiative stems from concerns raised by visually impaired patients who often rely on others to recognize medications, potentially compromising their autonomy and safety. The matter was first discussed at the 58th DCC meeting in July 2020, where a subcommittee was formed to explore detailed solutions. The subcommittee’s report put forward the following key recommendations for initial voluntary implementation:
-
Inclusion of Braille labels on medicines supplied in mono-carton packs to aid direct identification.
-
Special attention to medicines predominantly used by visually impaired patients, such as eye drops.
-
Exclusion of products administered under supervision, including injectables and vaccines, from these requirements.
-
Validation of Braille artwork by recognized agencies like the National Institute for the Empowerment of Persons with Intellectual Disabilities (NIEPID) via the Braille Council of India.
-
Adoption of font size and spacing standards for print information to maximize readability, referencing European guidelines.
-
Availability of package information leaflets in accessible formats upon request.
-
Advisory issuance to retail pharmacists for verbal guidance on dosages, indications, expiry dates, and other critical information for visually impaired customers.
Further deliberations at the 66th DCC meeting in June 2025 expanded these proposals by suggesting additional measures such as providing Braille cards with secondary packaging containing more than ten units and integrating QR codes linked to voice assistance technologies on medicine packs.
Expert Perspectives
Dr. Anjali Menon, a leading ophthalmologist not associated with the CDSCO committee, applauds the initiative, stating, “This proposal addresses a long-neglected barrier to medicine adherence among visually impaired patients. Clear labeling and voice-assisted technology can significantly reduce medication errors and foster independence.” She emphasizes that accurate medicine identification is crucial for patient safety and effective treatment.
Contextual Background and Global Comparisons
Globally, accessible medicine labeling has gained increased attention as part of broader efforts to improve healthcare equity. For instance, European Union regulations have long mandated certain accessibility standards, including Braille on packaging, to assist individuals with visual impairments. The proposed CDSCO measures align India with such international best practices, though currently on a voluntary basis, reflecting an incremental approach mindful of industry and logistical challenges.
Implications for Public Health and Patients
If implemented effectively, these measures could lead to enhanced patient safety by reducing errors in medicine intake and promoting autonomy among visually impaired individuals. Moreover, making package leaflets available in accessible formats and providing verbal counseling at pharmacies can reinforce these benefits. This also underscores the role of healthcare professionals and pharmacists in supporting inclusive care.
Limitations and Considerations
While the proposal is promising, certain limitations warrant attention. The initial voluntary nature of the guidelines may result in inconsistent adoption across manufacturers, potentially limiting accessibility gains. The focus on mono-carton packs excludes multi-unit packaging, although the provision of Braille cards partially addresses this. Moreover, successful implementation requires robust validation mechanisms for Braille accuracy and effective dissemination of training for pharmacists and retailers to provide appropriate verbal guidance.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Central Drugs Standard Control Organisation. “Inviting comments on accessibility measures for visually impaired persons.” Official notice, 2025. Available: https://medicaldialogues.in/pdf_upload/inviting-comments-wrt-visually-impaired-people-300497.pdf
